The Zacks Medical sector has struggled in 2023, down roughly 5% YTD and underperforming relative to the S&P 500.
One stock residing in the realm, Pfizer (PFE - Free Report) , has seen its near-term outlook shift negative over the last several months, pushing the stock down into a Zacks Rank #5 (Strong Sell).
Pfizer is a multinational pharmaceutical and biotechnology corporation headquartered in New York City, well-known for its COVID-19 vaccine. How does the company currently stack up? Let’s take a closer look.
Share Performance
PFE shares have been in a downward trend throughout 2023, losing more than 20% in value and widely underperforming relative to the S&P 500.
And over the last six months, PFE shares have again lagged behind the general market, losing 6% in value compared to the S&P 500’s 9% gain. The adverse price action indicates that sellers have been in control with no meaningful buying yet to step up.
Quarterly Performance
Pfizer has consistently posted better-than-expected results recently, exceeding earnings and revenue estimates in three consecutive quarters. Just in its latest release, the pharmaceutical titan penciled in a 10% bottom line beat and reported sales marginally above expectations.
However, the market wasn’t impressed with the recent double-beat, sending shares downward post-earnings. This is illustrated by the green arrow circled in the chart below.
Dividends
Pfizer shares do pay a solid dividend, currently yielding 4.1% annually. As we can see, the current yield is more than double the average of the Zacks Medical sector.
Over the last five years, PFE’s payout has grown by roughly 4%.
Bottom Line
Weak share performance and negative earnings estimate revisions from analysts paint a challenging picture for the company’s shares in the near term.
Pfizer (PFE - Free Report) is a Zacks Rank #5 (Strong Sell), indicating that analysts have taken a bearish stance on the company’s earnings outlook over the last several months.
For those seeking strong stocks, a great idea would be to focus on stocks carrying a Zacks Rank #1 (Strong Buy) or a Zacks Rank #2 (Buy) – these stocks sport a notably stronger earnings outlook paired with the potential to deliver explosive gains in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
The Zacks Medical sector has struggled in 2023, down roughly 5% YTD and underperforming relative to the S&P 500.
One stock residing in the realm, Pfizer (PFE - Free Report) , has seen its near-term outlook shift negative over the last several months, pushing the stock down into a Zacks Rank #5 (Strong Sell).
Pfizer is a multinational pharmaceutical and biotechnology corporation headquartered in New York City, well-known for its COVID-19 vaccine. How does the company currently stack up? Let’s take a closer look.
Share Performance
PFE shares have been in a downward trend throughout 2023, losing more than 20% in value and widely underperforming relative to the S&P 500.
And over the last six months, PFE shares have again lagged behind the general market, losing 6% in value compared to the S&P 500’s 9% gain. The adverse price action indicates that sellers have been in control with no meaningful buying yet to step up.
Quarterly Performance
Pfizer has consistently posted better-than-expected results recently, exceeding earnings and revenue estimates in three consecutive quarters. Just in its latest release, the pharmaceutical titan penciled in a 10% bottom line beat and reported sales marginally above expectations.
However, the market wasn’t impressed with the recent double-beat, sending shares downward post-earnings. This is illustrated by the green arrow circled in the chart below.
Dividends
Pfizer shares do pay a solid dividend, currently yielding 4.1% annually. As we can see, the current yield is more than double the average of the Zacks Medical sector.
Over the last five years, PFE’s payout has grown by roughly 4%.
Bottom Line
Weak share performance and negative earnings estimate revisions from analysts paint a challenging picture for the company’s shares in the near term.
Pfizer (PFE - Free Report) is a Zacks Rank #5 (Strong Sell), indicating that analysts have taken a bearish stance on the company’s earnings outlook over the last several months.
For those seeking strong stocks, a great idea would be to focus on stocks carrying a Zacks Rank #1 (Strong Buy) or a Zacks Rank #2 (Buy) – these stocks sport a notably stronger earnings outlook paired with the potential to deliver explosive gains in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on PFE - FREE